ITC: Horlicks, Complan valuations too high to buy

BENGALURU: ITC pulled out of the race to buy Horlicks and Complan because it considered the valuations of these brands too high and something which did not fit into its portfolio, a top executive said. The company has already indicated that it is keen to get into the health food segment and now that it is out of contention for the two products, it will in all probability, build one of its own to diversify. ITC pulled the plug for GlaxoSmithKlineowned Horlicks bid early while it showed scant interest in Complan, owned by Kraft Heinz.

“These were opportunities that just came up in the last few months. We evaluated and looked at some of these valuations and found the cost of acquisition to be very high. Given the high FMCG valuations in India, such acquisitions could be a challenge. In this context, we are not pursuing it,” Hemant Malik, divisional chief executive of ITC Foods, told TOI.

Malik agreed that the health drinks segment is an interesting space, something that will be part of the company’s future portfolio and a space that cannot be “ignored”. “We will be looking at that space through our new brand.” The bid for Horlicks has attracted global conglomerates Nestle, Unilever, Reckitt Benckiser, Kellogg’s and even Pepsi and Coca-Cola. The cola giants are looking to diversify beyond their stronghold of sugary carbonated drinks at a time when consumers are looking out for healthier options.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Centre Urges States To Enforce Clinical Establishments Act & Standardise Hospital Rates

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid